Cargando…

Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series

OBJECTIVE: Although the treatment of non-small-cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) alterations has been studied for years, the overall response rate (ORR) of these patients is still unsatisfactory, and more therapeutic strategies are needed. Little...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Shuang, Xian, Xinghong, Tian, Panwen, Li, Weimin, Wang, Ke, Li, Yalun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093620/ https://www.ncbi.nlm.nih.gov/pubmed/33959501 http://dx.doi.org/10.3389/fonc.2021.633522

Ejemplares similares

Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression
por: Zhang, Chuan, et al.
Publicado: (2023)

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
por: Zeng, Hao, et al.
Publicado: (2021)

First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis
por: Liu, Qiao, et al.
Publicado: (2021)

Chemo-immunotherapy as first-line treatment for small-cell lung cancer
por: Farid, Saira, et al.
Publicado: (2020)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer
por: Mei, Lihong, et al.
Publicado: (2023)

Cost-Effectiveness of Pembrolizumab for the treatment of Non–Small-Cell lung cancer: A systematic review
por: Zhang, Chuan, et al.
Publicado: (2022)

Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma
por: Wu, Zuohong, et al.
Publicado: (2021)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma
por: Tostes, Francinne T., et al.
Publicado: (2022)

A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis
por: Lara-Velazquez, Montserrat, et al.
Publicado: (2021)

The clinical features and prognosis of fungal pleural infection: A case series and literature review
por: Jing, Yawan, et al.
Publicado: (2023)

Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
por: Li, Lingling, et al.
Publicado: (2020)

The full management from first-line to third-line treatments in patients with Her-2–negative advanced gastric cancer
por: Chang, Chunxiao, et al.
Publicado: (2022)

Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer
por: Alì, Greta, et al.
Publicado: (2023)

Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib
por: Wang, Ye, et al.
Publicado: (2020)

A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance
por: Wang, Ye, et al.
Publicado: (2019)

Case Report: An “Immune-Cold” EGFR Mutant NSCLC With Strong PD-L1 Expression Shows Resistance to Chemo-Immunotherapy
por: Zhao, Qian, et al.
Publicado: (2022)

Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma
por: Kaplon, Hélène
Publicado: (2022)

Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report
por: Inno, Alessandro, et al.
Publicado: (2023)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Xiong, Anwen, et al.
Publicado: (2021)

Common nutritional/inflammatory indicators are not effective tools in predicting the overall survival of patients with small cell lung cancer undergoing first-line chemotherapy
por: Tian, Huohuan, et al.
Publicado: (2023)

Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives
por: Luo, Wenxin, et al.
Publicado: (2021)

Editorial: Chemo-Resistance in Gastrointestinal Cancers
por: Li, Xia, et al.
Publicado: (2022)

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
por: Pelicon, Veronika, et al.
Publicado: (2023)

To Chemo or Not to Chemo… That Is the Question
por: Martin, Maria Felisa Eva B., et al.
Publicado: (2023)

A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report
por: Deng, Ling, et al.
Publicado: (2022)

Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer
por: Urakçı, Zuhat, et al.
Publicado: (2023)

Case Report: Pathological Complete Response in a Brain-Metastatic Lung Squamous Cell Carcinoma Patient With Long-Term Benefit From Chemo-Immunotherapy
por: Hu, Chen, et al.
Publicado: (2021)

GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up
por: Caraglia, Michele, et al.
Publicado: (2019)

AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study
por: Dai, Wangshu, et al.
Publicado: (2021)

The modulation of ion channels in cancer chemo-resistance
por: Zhao, Jiayu, et al.
Publicado: (2022)

Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients
por: Orillard, Emeline, et al.
Publicado: (2022)

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
por: Al Mahmasani, Layal, et al.
Publicado: (2023)

Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
por: Xie, Zhaoliang, et al.
Publicado: (2023)

A novel vector for magnetic resonance imaging-guided chemo-photothermal therapy for cancer
por: Kong, Ji chuan, et al.
Publicado: (2022)

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study
por: Yang, Guangjian, et al.
Publicado: (2022)

Predictive Model and Precaution for Oral Mucositis During Chemo-Radiotherapy in Nasopharyngeal Carcinoma Patients
por: Li, Pei-Jing, et al.
Publicado: (2020)

Chemo Heart
por: DeFilippis, Ersilia M.
Publicado: (2017)

HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
por: Zhang, Xinyong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_igflp9pa655f9prnb8clsnp4jl